HCM II Acquisition Corp. Unit (HONDU) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
HCM II Acquisition Corp. Unit stock (HONDU) is currently trading at $21.00. WallStSmart rates HONDU as Sell.
- HONDU PE ratio analysis and historical PE chart
- HONDU PS ratio (Price-to-Sales) history and trend
- HONDU intrinsic value — DCF, Graham Number, EPV models
- HONDU stock price prediction 2025 2026 2027 2028 2029 2030
- HONDU fair value vs current price
- HONDU insider transactions and insider buying
- Is HONDU undervalued or overvalued?
- HCM II Acquisition Corp. Unit financial analysis — revenue, earnings, cash flow
- HONDU Piotroski F-Score and Altman Z-Score
- HONDU analyst price target and Smart Rating
HCM II Acquisition Corp. Unit
📊 No data available
Try selecting a different time range
Smart Analysis
HCM II Acquisition Corp. Unit (HONDU) · 2 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around institutional own.. Significant fundamental concerns warrant caution or avoidance.
HCM II Acquisition Corp. Unit (HONDU) Key Strengths (0)
HCM II Acquisition Corp. Unit (HONDU) Areas to Watch (2)
Very low institutional interest at 0.17%
Small-cap company with higher risk but more growth potential
HCM II Acquisition Corp. Unit (HONDU) Detailed Analysis Report
Overall Assessment
This company scores 5/100 in our Smart Analysis, earning a F grade. Out of 2 metrics analyzed, 0 register as strengths (avg 0/10) while 2 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Institutional Own., Market Cap.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Institutional Own. and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HONDU Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:27:54 AM
About HCM II Acquisition Corp. Unit(HONDU)
NASDAQ
FINANCIAL SERVICES
SHELL COMPANIES
USA
HCM II Acquisition Corp. is a special purpose acquisition company (SPAC) targeting mergers and acquisitions within the dynamic healthcare sector. Leveraging a team of seasoned professionals and strategic partnerships, the firm is positioned to identify and enhance value in high-growth healthcare enterprises. By focusing on emerging trends and innovative solutions, HCM II aims to capitalize on transformative opportunities in the industry, presenting institutional investors with a compelling avenue to gain exposure to the evolving landscape of healthcare.